Tao Wu

This inventor holds 89 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 16 EPO patents, primarily in Cancer Therapeutics (CPC class C07D403-04). Top assignees: Araxes Pharma LLC, Intel Corporation, Kura Oncology, Inc.. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tao Wu. Retrieved from https://idiyas.com/inventor/tao-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 89 (Patent Applications = 19)

% Patents Active = 78.7

CIPO Patents = 4 (Patent Applications = 10)

EPO Patents = 16 (Patent Applications = 27)

Average Co-Inventor Count = 4.1

ph-index = 16

Forward Citations = 737(Granted Patents)

Forward Citations (Not Self Cited) = 450(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

La Jolla, CA (US) (2019)
Chandler, AZ (US) (2012 - 2022)
San Jose, CA (US) (2018 - 2022)
Carlsbad, CA (US) (2008 - 2024)
San Diego, CA (US) (2013 - 2024)

Company Filing History:

Future Wei Technologies, Inc.

patents

5. 10 out of 3,543

University of Michigan

patents

6. 8 out of 27,041

Telefonaktiebolaget Lm Ericsson (Publ)

Ford Global Technolgoies, LLC

Life Technologies Corporation

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

Covalent Inhibitors

KRAS G12C

Quinazoline Compounds

Menin-MLL

Hematological Malignancies

Cancer Treatment

Inhibitors

Thienopyrimidine

Spiro Compounds

Bicyclic Inhibitors

Ewing's Sarcoma

5G V2X Communications

89 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50527 - Covalent inhibitors of KRAS G12C (2025-08-12),

2. RE50490 - Substituted quinazoline compounds and methods of use thereof (2025-07-15),

3. 12234244 - Substituted piperazines as inhibitors of KRAS G12C (2025-02-25),

4. 12134620 - Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer (2024-11-05),

5. 11944627 - Methods for treating hematological malignancies and Ewing's sarcoma (2024-04-02),

6. 11878985 - Substituted quinazolines as inhibitors of KRAS G12C (2024-01-23),

7. RE49687 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2023-10-10),

8. 11673898 - Substituted inhibitors of menin-MLL and methods of use (2023-06-13),

9. 11649251 - Substituted inhibitors of menin-MLL and methods of use (2023-05-16),

10. 11639346 - Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS (2023-05-02),

11. 11555041 - Bridged bicyclic inhibitors of menin-MLL and methods of use (2023-01-17),

12. 11542248 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2023-01-03),

13. 11533675 - System and methods for system operation for narrowband-LTE for cellular IoT (2022-12-20),

14. 11516915 - Reduced capacitance land pad (2022-11-29),

15. 11443970 - Methods of forming a package substrate (2022-09-13),

Title: Unveiling the Innovations of Inventor Tao Wu

Introduction: In the realm of cutting-edge inventions, one name shines brightly - Tao Wu, a prolific inventor hailing from Carlsbad, CA, USA. With an impressive portfolio of 84 patents, Tao Wu has made significant strides in the field of pharmaceuticals and disease treatment. Let's delve into the realm of his latest patents, career highlights, and noteworthy collaborations.

Latest Patents: Tao Wu's recent patents encompass groundbreaking innovations such as "Substituted quinazolines as inhibitors of KRAS G12C" and "Thienopyrimidine and thienopyridine compounds." These inventions offer promising avenues for treating cancer and other diseases by targeting specific proteins and signaling pathways crucial for disease progression.

Career Highlights: Throughout his career, Tao Wu has lent his inventive prowess to esteemed companies like Araxes Pharma LLC and Intel Corporation. His contributions have not only led to novel patents but also advanced the frontiers of scientific research in the pharmaceutical and biotechnological domains.

Collaborations: In his journey of innovation, Tao Wu has collaborated with accomplished peers such as Liansheng Li and Pingda Ren. Together, they have synergized their expertise to develop cutting-edge solutions for combating diseases and addressing unmet medical needs.

Conclusion: Inventor Tao Wu's visionary inventions and impactful collaborations underscore his role as a trailblazer in the field of pharmaceutical innovation. His relentless pursuit of scientific excellence continues to inspire and pave the way for transformative breakthroughs in healthcare and beyond.

Profile summary based on public USPTO records.